2022年11月 | 失败临床研究TOP10
[1] https://www.roche.com/media/releases/med-cor-2022-11-14
[2] https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-clinical-data-demonstrating-proof
[3] https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/
[4] https://ir.nextcure.com/news-releases/news-release-details/nextcure-provides-update-and-reports-third-quarter-2022
[5] https://investors.satsumarx.com/2022-11-14-Satsuma-Pharmaceuticals-Announces-Topline-Results-from-SUMMIT-Phase-3-Trial-of-STS101-for-the-Acute-Treatment-of-Migraine
[6] https://www.fiercebiotech.com/biotech/novartis-halts-phase-1-cd73-antagonist-over-efficacy-combo-trials-continue
[7] https://investor.neoleukin.com/news-releases/news-release-details/neoleukin-therapeutics-announces-third-quarter-2022-financial
[8] https://www.cincor.com/news-releases/news-release-details/cincor-pharma-announces-topline-data-phase-2-halo-trial
[9] https://www.rigel.com/investors/news-events/press-releases/detail/345/rigel-announces-top-line-results-from-focus-phase-3
[10] https://endpts.com/regeneron-culls-two-drugs-from-pipeline-amid-double-digit-revenue-drop-after-covid-mab-cocktail-pull/